The introduction and subsequent iterations of drug-eluting stent technologies have
substantially improved the efficacy and safety of percutaneous coronary interventions …

Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …

These Guidelines represent the third time that the ESC and EACTS have brought together
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known
as “restenosis”. This phenomenon is due to vessel remodeling/recoil in case of no-stent …

Zachęca się pracowników opieki zdrowotnej, aby w pełni uwzględniali te wytyczne
ESC/EACTS, gdy dokonują oceny klinicznej, a także kiedy określają i realizują medyczne …

Aims Consensus is lacking regarding the best treatment for coronary in-stent restenosis
(ISR). The two most effective treatments are angioplasty with paclitaxel-coated balloon …

Management of patients with in-stent restenosis (ISR) remains an important clinical problem.
Although drug-eluting stents (DES) have drastically reduced the incidence of ISR, treatment …

In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous
coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI …